Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model
Open Access
- 27 March 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3098
Abstract
Sarcopenia, a serious consequence of chronic kidney disease (CKD), is driven by elevated myostatin (MSTN), a key inhibitor of muscle growth. This study explored the potential of an MSTN-specific antisense oligonucleotide (ASO) in reversing CKD-induced muscle wasting in a mouse model. Thirty-two male C57BL/6J mice were randomly assigned to a non-CKD group (n = 8, regular diet) and a CKD group (n = 24, adenine diet). CKD was induced using a 0.2% adenine-supplemented diet for 4 weeks. Following this, the mice were sub-grouped into CKD (saline, n = 8), CKD + Low-Dose ASO (25 mg/kg ASO, n = 8), and CKD + High-Dose ASO (50 mg/kg ASO, n = 8). ASO was administered via subcutaneous injections for 8 weeks. Muscle mass, treadmill performance, grip strength, and muscle fiber morphology were assessed alongside qPCR and Western blot analysis for MSTN, atrogin-1, and MuRF-1 expression. ASO therapy significantly enhanced muscle mass and function and enlarged muscle fibers while effectively downregulating muscle degradation markers. These improvements occurred without compromising renal function, as confirmed by BUN, creatinine, kidney weight, and histological analysis. This study is the first to demonstrate the efficacy of ASO therapy in mitigating CKD-induced sarcopenia, offering a promising targeted gene therapy with significant clinical implications for improving nutritional status and physical performance in CKD.Keywords
Funding Information
- Research Project for Practical Application of Rare and Intractable Diseases, Japan Agency for Medical Research and Development (AMED) (JP23ek0109665h0001)
This publication has 81 references indexed in Scilit:
- Myostatin Knockout Mice Have Larger Muscle Fibers With Normal Function and MorphologyMuscle & Nerve, 2025
- Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With SarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2025
- Irisin Ameliorates Muscle Atrophy by Inhibiting the Upregulation of the Ubiquitin‒Proteasome System in Chronic Kidney DiseaseCalcified Tissue International, 2024
- Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin‐Deficient Diabetic MiceJBMR Plus, 2023
- Skeletal muscle myostatin mRNA expression is upregulated in aged human adults with excess adiposity but is not associated with insulin resistance and ageingGeroScience, 2023
- Resistance exercise and nutritional interventions for augmenting sarcopenia outcomes in chronic kidney disease: a narrative reviewJournal of Cachexia, Sarcopenia and Muscle, 2021
- Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and TreatmentCalcified Tissue International, 2021
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophyJournal of Cachexia, Sarcopenia and Muscle, 2020
- Suppression of muscle wasting by the plant‐derived compound ursolic acid in a model of chronic kidney diseaseJournal of Cachexia, Sarcopenia and Muscle, 2016